Avatrombopag

Generic Name: Avatrombopag

Brand Names: Doptelet 60 Mg Daily Dose Carton, Doptelet

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₄Cl_₂N_₆O_₃S_₂

CAS Number: 570406-98-3

Unique Ingredient Identifier: 3H8GSZ4SQL

Background: Avatrombopag (Doptelet), is an orally administered, small-molecule thrombopoietin receptor (c-Mpl) agonist which increases platelet number, but not platelet activation , . This decreases the need for blood transfusions .
...

Indication: Indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure .

Associated Conditions: Thrombocytopenia

Associated Therapies: -

Clinical Trials

Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia

Phase 2

Recruiting

Conditions: Treatment
Immune Thrombocytopenia

Interventions: Drug: Avatrombopag

First Posted Date: 2024-02-28

Last Posted Date: 2024-02-28

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 60

Registration Number: NCT06281327

Locations: 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

Efficacy and Safety of Avatrombopag vs. Avatrombopag Combined With rhTPO in the Treatment of SAA

Phase 2

Not yet recruiting

Conditions: Anemia, Aplastic

Interventions: Drug: Avatrombopag
Drug: Avatrombopag +rhTPO

First Posted Date: 2024-02-12

Last Posted Date: 2024-02-12

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 60

Registration Number: NCT06254287

Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT

Phase 2

Recruiting

Conditions: Stem Cell Transplant Complications
Thrombocytopenia

Interventions: Drug: Placebo
Drug: avatrombopag

First Posted Date: 2024-01-11

Last Posted Date: 2024-10-01

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 142

Registration Number: NCT06202625

Locations: 🇨🇳
Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China
🇨🇳
Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

and more 11 locations

Efficacy and Safety of CsA+AVA in the Treatment of NSAA in the Elderly

Phase 2

Recruiting

Conditions: Aplastic Anemia

Interventions: Drug: Ciclosporin
Drug: Avatrombopag

First Posted Date: 2023-08-22

Last Posted Date: 2023-12-08

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 30

Registration Number: NCT06004752

Locations: 🇨🇳
Peking union medical college hospital, Beijing, China

Avatrombopag for HCC Patients With Thrombocytopenia Who Intend to Undergo TACE and/or HAIC

Phase 2

Recruiting

Conditions: Thrombocytopenia
Hepatocellular Carcinoma

Interventions: Drug: Avatrombopag

First Posted Date: 2023-08-21

Last Posted Date: 2023-09-14

Lead Sponsor: Second Affiliated Hospital of Guangzhou Medical University

Target Recruit Count: 30

Registration Number: NCT06001567

Locations: 🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly

Phase 4

Not yet recruiting

Conditions: Aplastic Anemia

Interventions: Drug: Ciclosporin
Drug: Avatrombopag
Drug: Anti-Human Thymocyte Immunoglobulin, Rabbit

First Posted Date: 2023-08-18

Last Posted Date: 2023-08-18

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 60

Registration Number: NCT05996393

Locations: 🇨🇳
Peking union medical college hospital, Beijing, China

Avatrombopag for Platelet Recovery Post-UCBT in Patients With Bone Marrow Failure Disease

Recruiting

Conditions: Platelet Recovery After Umbilical Cord Blood Transplantation

Interventions: Drug: Avatrombopag

First Posted Date: 2023-04-21

Last Posted Date: 2023-10-06

Lead Sponsor: Anhui Provincial Hospital

Target Recruit Count: 40

Registration Number: NCT05823376

Locations: 🇨🇳
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui, China

Avatrombopag Vs. Placebo for CIT in GI Malignancies

Phase 2

Recruiting

Conditions: Gastrointestinal Cancer
Gastrointestinal Neoplasms
Chemotherapy-Induced Thrombocytopenia

Interventions: Drug: Avatrombopag
Drug: Matching Placebo

First Posted Date: 2023-03-16

Last Posted Date: 2024-10-31

Lead Sponsor: Hanny Al-Samkari, MD

Target Recruit Count: 60

Registration Number: NCT05772546

Locations: 🇺🇸
Yale New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 2 locations

Avatrombopag Combined With IST as First-line Treatment for SAA

Phase 2

Recruiting

Conditions: Severe Aplastic Anemia

Interventions: Drug: avatrombopag

First Posted Date: 2023-02-09

Last Posted Date: 2023-02-09

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 53

Registration Number: NCT05720234

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

The Safety and Efficacy Study of Avatrombopag Switch in TPO-RA Refractory AA

Not Applicable

Recruiting

Conditions: Refractory Aplastic Anemia

Interventions: Drug: avatrombopag

First Posted Date: 2022-08-26

Last Posted Date: 2022-08-26

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 39

Registration Number: NCT05518331

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy